Expression and production of the SERPING1-encoded endogenous complement regulator C1-inhibitor in multiple cohorts of tuberculosis patients.


Journal

Molecular immunology
ISSN: 1872-9142
Titre abrégé: Mol Immunol
Pays: England
ID NLM: 7905289

Informations de publication

Date de publication:
04 2020
Historique:
received: 21 10 2019
revised: 03 02 2020
accepted: 10 02 2020
pubmed: 18 3 2020
medline: 14 4 2020
entrez: 18 3 2020
Statut: ppublish

Résumé

To facilitate better discrimination between patients with active tuberculosis (TB) and latent TB infection (LTBI), whole blood transcriptomic studies have been performed to identify novel candidate host biomarkers. SERPING1, which encodes C1-inhibitor (C1-INH), the natural inhibitor of the C1-complex has emerged as candidate biomarker. Here we collated and analysed SERPING1 expression data and subsequently determined C1-INH protein levels in four cohorts of patients with TB. SERPING1 expression data were extracted from online deposited datasets. C1-INH protein levels were determined by ELISA in sera from individuals with active TB, LTBI as well as other disease controls in geographically diverse cohorts. SERPING1 expression was increased in patients with active TB compared to healthy controls (8/11 cohorts), LTBI (13/14 cohorts) and patients with other (non-TB) lung-diseases (7/7 cohorts). Serum levels of C1-INH were significantly increased in The Gambia and Italy in patients with active TB relative to the endemic controls but not in South Africa or Korea. In the largest cohort (n = 50), with samples collected longitudinally, normalization of C1-INH levels following successful TB treatment was observed. This cohort, also showed the most abundant increase in C1-INH, and a positive correlation between C1q and C1-INH levels. Combined presence of increased levels of both C1q and C1-INH had high specificity for active TB (96 %) but only very modest sensitivity 38 % compared to the endemic controls. SERPING1 transcript expression is increased in TB patients, while serum protein levels of C1-INH were increased in half of the cohorts analysed.

Sections du résumé

BACKGROUND
To facilitate better discrimination between patients with active tuberculosis (TB) and latent TB infection (LTBI), whole blood transcriptomic studies have been performed to identify novel candidate host biomarkers. SERPING1, which encodes C1-inhibitor (C1-INH), the natural inhibitor of the C1-complex has emerged as candidate biomarker. Here we collated and analysed SERPING1 expression data and subsequently determined C1-INH protein levels in four cohorts of patients with TB.
METHODS
SERPING1 expression data were extracted from online deposited datasets. C1-INH protein levels were determined by ELISA in sera from individuals with active TB, LTBI as well as other disease controls in geographically diverse cohorts.
FINDINGS
SERPING1 expression was increased in patients with active TB compared to healthy controls (8/11 cohorts), LTBI (13/14 cohorts) and patients with other (non-TB) lung-diseases (7/7 cohorts). Serum levels of C1-INH were significantly increased in The Gambia and Italy in patients with active TB relative to the endemic controls but not in South Africa or Korea. In the largest cohort (n = 50), with samples collected longitudinally, normalization of C1-INH levels following successful TB treatment was observed. This cohort, also showed the most abundant increase in C1-INH, and a positive correlation between C1q and C1-INH levels. Combined presence of increased levels of both C1q and C1-INH had high specificity for active TB (96 %) but only very modest sensitivity 38 % compared to the endemic controls.
INTERPRETATION
SERPING1 transcript expression is increased in TB patients, while serum protein levels of C1-INH were increased in half of the cohorts analysed.

Identifiants

pubmed: 32179338
pii: S0161-5890(19)30735-7
doi: 10.1016/j.molimm.2020.02.006
pii:
doi:

Substances chimiques

Biomarkers 0
Complement C1 Inhibitor Protein 0
SERPING1 protein, human 0
Complement C1q 80295-33-6

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

187-195

Subventions

Organisme : Medical Research Council
ID : MC_U190071468
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_A900_1122
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R21 AI127133
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Rosalie Lubbers (R)

Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.

Jayne S Sutherland (JS)

Vaccines and Immunity Theme, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.

Delia Goletti (D)

Translational Research Unit, Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy.

Roelof A de Paus (RA)

Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.

Douwe J Dijkstra (DJ)

Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands.

Coline H M van Moorsel (CHM)

Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands.

Marcel Veltkamp (M)

Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands.

Stefan M T Vestjens (SMT)

Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, the Netherlands.

Willem J W Bos (WJW)

Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, the Netherlands; Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands.

Linda Petrone (L)

Translational Research Unit, Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome, Italy.

Stephanus T Malherbe (ST)

DST/NRF Centre of Excellence for Biomedical TB Research and SAMRC Centre for TB Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Gerhard Walzl (G)

DST/NRF Centre of Excellence for Biomedical TB Research and SAMRC Centre for TB Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Kyra A Gelderman (KA)

Sanquin Diagnostic Services, Amsterdam, the Netherlands.

Geert H Groeneveld (GH)

Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.

Annemieke Geluk (A)

Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.

Tom H M Ottenhoff (THM)

Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.

Simone A Joosten (SA)

Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.

Leendert A Trouw (LA)

Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: L.A.Trouw@lumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH